Skip to main content
Expert Insights

Bruce Sands, MD, on the FUZION Study of Guselkumab for Perianal Fistulizing Crohn's DIsease

Dr Sands reviews the results of the FUZION study of guselkumab in the treatment of perianal fistulizing Crohn's disease, which he presented at both the American College of Gastroenterology Scientific Conference and United European Gastroenterology Week.

 

Bruce Sands, MD, MS, is the Dr. Burrill B. Crohn Professor of Medicine and chief of the Dr. Henry D. Janowitz Division of Gastroenterology at the Icahn School of Medicine at Mt Sinai in New York, New York.

Clinical Practice Summary

Guselkumab Improves Perianal Fistula Remission in Phase 3 FUZION

  • FUZION, a randomized, double-blind, placebo-controlled phase 3 trial, evaluated guselkumab in 286 patients with active perianal fistulizing Crohn’s disease; approximately two-thirds had prior biologic exposure, predominantly anti-TNFs.
  • Week 24 combined clinical and radiologic fistula remission occurred in 28.3% receiving guselkumab 100 mg subcutaneously every 8 weeks and 27% receiving 200 mg every 4 weeks versus 10.3% receiving placebo; both comparisons were statistically significant.
  • Remission rates remained stable through week 48, and no new types of adverse events emerged compared with previous guselkumab studies.

Transcript

Okay. I'm Bruce Sands. I'm chief of the Division of Gastroenterology at Mount Sinai in New York, and I'm here to talk about the FUZION study. FUZION was a study looking at patients with Crohn's disease that had perianal fistulization, and this is a very challenging problem for people with IBD, with Crohn's disease, and there's very little clinical trial data about the treatment of perianal fistulizing Crohn's disease. In fact, you would have to go back as far as ACCENT II, which was a study of perianal fistulizing Crohn's disease published in 2004, demonstrating the efficacy of infliximab, which really has become the standard of care for medical therapy for treatment of fistulizing Crohn's disease.

Now, FUZION explored guselkumab, which is a selective dual-acting IL-23 inhibitor, and it blocks both IL-23 and CD64 on immune cells that produce IL-23. So the objective of the FUZION study was to engage in a phase 3 randomized placebo-controlled and double-blinded study to look at the efficacy and safety of guselkumab in patients with active perianal fistulizing Crohn's disease.

The structure of the study was randomization 2 to 1: Patients to get guselkumab 200 milligrams IV every 4 weeks by induction over 12 weeks, followed by 200 milligrams sub-q every 4 weeks, or 200 milligrams IV every 4 weeks induction followed by maintenance with 100 milligram sub-q 8 weeks. And then the placebo arm was basically 58 patients assigned to that. In total, 286 patients were randomized in this study.

Patients could have had setons, but setons had to be removed between weeks 4 and week 12, and then the patients were followed out to week 24 and subsequently to week 48 for long-term efficacy and closure of fistulas. The randomization was stratified, importantly, by whether the patient had proctitis or not—that's an important factor in the ability to close perianal fistulas—and whether they were bio-naive or bio-experienced. And so the primary endpoint was what was called combined fistula remission at week 24, and this was both clinically and radiologically assessed.

Additionally, there were multiplicity controlled secondary endpoints, which include clinically assessed fistula remission at week 24 and clinically assessed fistula response at week 24, and secondary endpoints of radiologic assessment of fistula remission at week 24, and also assessment of fistula response at week 12. These patients all had one or more perianal fistula openings.  Many of them had had prior experience with biologic therapies. For the most part, these were anti-TNFs, which as I said, are the standard of care currently, and that was a fair number of patients who had been bio-exposed, really approximately two-thirds of patients were bio-exposed mostly to anti-TNFs.

And then talking about the results, combined fistula remission was achieved at week 24 in 28.3% of the patients who were maintained on 100 milligram sub-q every 8 weeks, 27% of patients on the 200 milligram sub-q every 4 weeks, and both of these were statistically significantly superior to placebo, where only 10.3% of patients achieved this outcome of combined fistula remission. The extension of the data out to week 48 showed that there was good maintenance of efficacy all the way out to week 48. Basically, the rates of combined fistula remission did not change over time.

Additionally, the safety of guselkumab was excellent. We did not see any new kinds of adverse events coming out in this study as compared to other studies looking at guselkumab, and we know that the anti-IL-23 antibodies are extraordinarily safe. So in summary, guselkumab induction and maintenance therapy was effective through week 24 and even through week 48 in a refractory population of patients who had perianal fistulizing Crohn's disease, and both of the maintenance doses showed statistically significant and clinically meaningful benefit as compared with placebo without any important adverse events coming through.

So I think this is very important work because it adds a new possible treatment for patients with perianal fistulizing Crohn's disease. And I think if you think about it now, guselkumab might be used as a first-line therapy for fistulizing Crohn's disease or as a second-line therapy after failure of an anti-TNF or other biologic therapies. So really, I think a very important study.

 

© 2026 HMP Global. All Rights Reserved.